Tactile Medical projects $360M-$366M 2026 revenue as airway clearance ordering normalizes in Q4 (NASDAQ:TCMD)

TCMD Q2 2026 earnings call recap: raised revenue guidance to $360–$366M, lymphedema strength, AffloVest inventory reset, Medicare prior auth impact—read...

Tactile Medical projects $360M-$366M 2026 revenue as airway clearance ordering normalizes in Q4 (NASDAQ:TCMD) | Seeking Alpha

Earnings Call Insights: Tactile Systems Technology (TCMD) Q2 2026

Management view

"We delivered another strong quarter of execution in Q2, highlighted by continued strength in our lymphedema business and meaningful profitability expansion." (CEO, President & Director Sheri Dodd)

"Based on

Seeking Alpha's Disclaimer:

This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Quick Insights

What are the main drivers of Tactile Systems Technology's updated 2026 revenue guidance?

Lymphedema business strength and launch of new distribution agreement with ElastiMed are boosting revenue, while airway clearance segment faces temporary inventory disruptions.

How are Medicare prior authorization and inventory management affecting TCMD's lymphedema and airway clearance businesses?

Medicare prior authorization has caused near-term moderation in lymphedema order volumes, and inventory management dynamics among DME partners have led to a temporary decline in airway clearance revenue, expected to normalize later in the year.

What is the impact of AffloVest inventory dynamics and product launches on TCMD's financial outlook?

AffloVest ordering dropped due to partners managing inventory post-next-gen launch; management expects this to continue through Q3 but normalize in Q4, with the potential for resumed growth once inventory levels rebalance.

Recommended For You

More

Trending News

See More

»